相关实验视频

Updated: Jul 1, 2025

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

对于RASopathy-Associated Hypertrophic Cardiomyopathy的MEK抑制:一个基本概念的临床应用

Dominic Chaput¹, Gregor Andelfinger¹

¹Cardiovascular Genetics Research Laboratory, CHU Sainte Justine Research Center, Department of Pediatrics, Université de Montréal, Montréal, Quebec, Canada.

The Canadian journal of cardiology

|March 3, 2024

概括

影响发育的遗传性疾病,可导致严重的心脏病. 药物重新定位,就像使用特拉美替尼或西洛斯一样,显示出治疗RASopathy相关心肌病的前景.

科学领域:

遗传学是一个遗传学.
心脏病学心脏病学
药理学药理学是指药理学的学科.

背景情况:

拉索病症是一种发育性综合征,由RAS/MAPK通路中的激活变异引起.
超性心肌病是一种严重的,危及生命的并发症,在10%的RASopathy患者中.
努南综合征是最常见的RAS病症,其他变体包括带有多个lentigines的努南综合征,科斯特洛综合征和心肌病皮肤综合征.

研究的目的:

审查RAS / MAPK途径在RASopathy相关心肌病中的作用.
讨论小分子抑制剂治疗这种疾病的潜力.
探索用于RASopathy心肌病的药物重定向策略.

主要方法:

关于心肌病中RAS/MAPK通路的文献综述.
关于对特拉美丁尼布 (MEK 抑制剂) 和西罗/埃弗洛 (mTOR 抑制剂) 的药物重新定位的讨论.
对基因型特异性治疗选择,监测和早期病例系列结果的分析.

主要成果:

针对RAS/MAPK通路的小分子抑制剂正在被重新用于RAS病变心肌病变.
早期病例系列的初步结果表明,特拉美提尼布,西洛利木斯和埃弗洛利木斯的潜在益处.
基因型特异性治疗选择是治疗方法的一个关键方面.

结论:

对RAS/MAPK通路抑制剂的药物重新定位为RAS病变相关心肌病的治疗概念提供了有前途的治疗方案.
需要进行进一步的临床试验,以量化这些重用药物的益处.
对于设计未来的试验来验证这些早期发现存在挑战和机会.

更多相关视频

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...